Compassionate use experience with gefitinib in poor performance (PS) patients with advanced non-small-cell lung cancer (NSCLC) treated in an expanded access program (EAP).

被引：0
|
作者：
Zinner, R
Govindan, R
Wozniak, AJ
Wade, JL
Belani, CP
Thienelt, CD
Hensing, TA
Reiling, RB
Natale, RB
Wiznitzer, I
机构：
[1] Univ Texas, MD Anderson Canc Ctr, Houston, TX 77030 USA
[2] Univ Washington, Sch Med, St Louis, MO USA
[3] Karmanos Canc Ctr, Detroit, MI USA
[4] Decatur Mem Hosp, Decatur, IL USA
[5] UPMC, Pittsburgh, PA USA
[6] Univ Colorado, Hlth Sci Ctr, Denver, CO USA
[7] Evanston NW Healthcare, Evanston, IL USA
[8] Presbyterian Canc Ctr, Charlotte, NC USA
[9] Cedars Sinai Comprehens Canc Ctr, Los Angeles, CA USA
[10] Lynn Reg Canc Ctr W, Boca Raton, FL USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2004年 / 22卷 / 14期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
7082
引用
收藏
页码：636S / 636S
页数：1
相关论文
共 50 条
  • [1] Clinical benefit with compassionate use gefitinib in a subset of non-small-cell lung cancer (NSCLC) patients with the bronchoalveolar (BAC) subtype treated during an expanded access program (EAP).
    Reiling, RB
    Wade, JL
    Govindan, R
    Wozniak, AJ
    Hensing, TA
    Koshy, S
    Thienelt, CD
    Natale, RB
    Belani, CP
    JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (14) : 638S - 638S
  • [2] Final survival and safety results for 21,064 non-small-cell lung cancer (NSCLC) patients who received compassionate use gefitinib in a US expanded access program (EAP).
    Ochs, J
    Grous, JJ
    Warner, KL
    JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (14) : 631S - 631S
  • [3] Iressa in advanced non-small-cell lung cancer (NSCLC) patients progressed to chemotherapy:: Spain expanded acces program (EAP) experience
    Castellano, D
    Neciosup, S
    Velasco, A
    Massuti, B
    Gomez, C
    Moyano, A
    Constenla, M
    López-Brea, M
    Taín, PD
    Cortes-Funes, H
    ANNALS OF ONCOLOGY, 2005, 16 : 306 - 307
  • [4] Gefitinib for patients with advanced non-small cell lung cancer treated on the expanded access program: a single institution experience
    de Souza Cruz, Marcelo Rocha
    Katz, Artur
    Gansl, Rene Claudio
    Tabacoff, Jacques
    Smaletz, Oren
    Simon, Sergio Daniel
    EINSTEIN-SAO PAULO, 2006, 4 (03): : 207 - 212
  • [5] Asian ethnicity as a predictor of response in patients with non-small-cell lung cancer treated with gefitinib on an expanded access program
    Thomas, Sheeba K.
    Fossella, Frank V.
    Liu, Diane
    Schaerer, Rainell
    Tsao, Anne S.
    Kies, Merrill S.
    Pisters, Katherine M.
    Blumenschein, George R., Jr.
    Glisson, Bonnie S.
    Lee, J. Jack
    Herbst, Roy S.
    Zinner, Ralph G.
    CLINICAL LUNG CANCER, 2006, 7 (05) : 326 - 331
  • [6] Efficacy and safety of gefitinib in chemo-naive patients with non-small cell lung cancer (NSCLC) in an expanded access program (EAP).
    Reding, RB
    Natale, R
    Wade, J
    Herbst, R
    Hensing, T
    Belani, CP
    Kelly, K
    Ochs, J
    Govindan, R
    Wozniak, A
    Krebs, A
    JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 643S - 643S
  • [7] Gefitinib in patients with advanced non-small cell lung cancer (NSCLC): The expanded access protocol experience at the University of Pennsylvania
    Veronese, ML
    Algazy, K
    Bearn, L
    Eaby, B
    Alavi, J
    Evans, T
    Stevenson, JP
    Shults, J
    CANCER INVESTIGATION, 2005, 23 (04) : 296 - 302
  • [8] Treatment of non-small-cell lung cancer with gefitinib (IRESSA) in a compassionate-use program: The Portuguese experience
    Araujo, A
    Teixeira, M
    Figueiredo, A
    Correia, J
    Melo, M
    Parente, B
    Bernardo, M
    Queiroga, H
    Barata, F
    LUNG CANCER, 2005, 49 : S234 - S234
  • [9] Gefitinib in treatment of advanced non-small-cell lung cancer as a last treatment option on an Expanded Access Program
    Zemanova, M
    Petruzelka, L
    Honova, H
    Dvorak, J
    Safanda, M
    Mares, P
    Tomancova, V
    LUNG CANCER, 2004, 45 : S82 - S82
  • [10] Gefitinib in treatment of advanced non-small-cell lung cancer as a last treatment option on an Expanded Access Program
    Zemanova, M
    Petruzelka, L
    Honova, H
    Dvorak, J
    Safanda, M
    Mares, P
    Tomancova, V
    LUNG CANCER, 2004, 45 : S82 - S83
12345